# Pathology-guided design of injectable hydrogels for precision therapy and cartilage regeneration in osteoarthritis

**Authors:** Zhi Zheng, Jiahao Xie, Junfa Zeng, Zhan Kang, Zhenqiu Liu, Mengzhen Qi, Cuiyun Yu, Hua Wei

PMC · DOI: 10.1093/rb/rbag009 · 2026-01-25

## TL;DR

This paper reviews how injectable hydrogels can be designed to precisely treat osteoarthritis by responding to joint microenvironment signals and delivering therapies for cartilage regeneration.

## Contribution

The paper introduces a systematic review of precision hydrogel design strategies tailored to osteoarthritis pathology for on-demand therapeutic delivery.

## Key findings

- Injectable hydrogels can dynamically respond to OA microenvironment signals for targeted drug, cell, and gene delivery.
- Current pharmacological and surgical methods for OA have significant limitations in structural and functional recovery.
- Smart hydrogels offer multifunctional platforms for cartilage regeneration through mechanical design and inflammation regulation.

## Abstract

Osteoarthritis (OA) is a highly prevalent degenerative joint disease whose complex pathological microenvironment and limited cartilage self-repair capacity have resulted in the absence of therapeutic approaches capable of simultaneously achieving structural reconstruction and functional recovery. Current clinical strategies face significant limitations, as conventional pharmacological treatments can only alleviate symptoms with accompanying systemic side effects, while surgical interventions often encounter challenges such as inadequate mechanical properties of repaired tissues and long-term degeneration. The precise functionalization of injectable hydrogels represents a key strategy for cartilage regeneration and the core challenge lies in integrating multiple material properties to design on-demand delivery platforms that can dynamically respond to complex pathological microenvironments in vivo. This review systematically elaborates on precision customization strategies for injectable hydrogels based on OA pathological mechanisms, focusing on how hydrogel design responds to pathological signals in the joint microenvironment to achieve on-demand and precise regulation of therapeutic agents including drugs, cells and genes. Beginning with cartilage structure and injury mechanisms, this article analyzes the limitations of existing pharmacological and surgical repair methods, then, elaborate on the multifunctional platform role of hydrogels in cartilage tissue engineering, including recent advances in mechanical design, drug loading/release behavior, inflammation regulation, stem cell delivery and gene-activated repair. Finally, it outlines challenges and future directions for smart hydrogels in cartilage regenerative medicine, aiming to provide a theoretical framework and technical pathway for integrating materials science with clinical medicine.

## Linked entities

- **Diseases:** Osteoarthritis (MONDO:0005178)

## Full-text entities

- **Genes:** CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, FGF18 (fibroblast growth factor 18) [NCBI Gene 8817] {aka FGF-18, ZFGF5}, TNFSF11 (TNF superfamily member 11) [NCBI Gene 8600] {aka CD254, ODF, OPGL, OPTB2, RANKL, TNLG6B}, PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562] {aka AMPK, AMPK alpha 1, AMPKa1}, ACAN (aggrecan) [NCBI Gene 176] {aka AGC1, AGCAN, CSPG1, CSPGCP, MSK16, SEDK}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, Tgfb3 (transforming growth factor, beta 3) [NCBI Gene 21809] {aka TGF-beta-3, Tgfb-3}, SOX9 (SRY-box transcription factor 9) [NCBI Gene 6662] {aka CMD1, CMPD1, ENH13, SRA1, SRXX2, SRXY10}, TAOK1 (TAO kinase 1) [NCBI Gene 57551] {aka DDIB, KFC-B, MAP3K16, MARKK, PSK-2, PSK2}, COL10A1 (collagen type X alpha 1 chain) [NCBI Gene 1300], EPAS1 (endothelial PAS domain protein 1) [NCBI Gene 2034] {aka ECYT4, HIF2A, HLF, MOP2, PASD2, bHLHe73}, USP7 (ubiquitin specific peptidase 7) [NCBI Gene 7874] {aka C16DELp13.2, DEL16P13.2, HAFOUS, HAUSP, TEF1}, MIR140 (microRNA 140) [NCBI Gene 406932] {aka MIRN140, SEDN, miRNA140, mir-140}, Mmp13 (matrix metallopeptidase 13) [NCBI Gene 17386] {aka Clg, MMP-13, Mmp1}, ADCYAP1 (adenylate cyclase activating polypeptide 1) [NCBI Gene 116] {aka PACAP}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, MMP13 (matrix metallopeptidase 13) [NCBI Gene 4322] {aka CLG3, MANDP1, MDST, MMP-13}, Pdlim3 (PDZ and LIM domain 3) [NCBI Gene 114108] {aka Actn2lp, Alp}, COL2A1 (collagen type II alpha 1 chain) [NCBI Gene 1280] {aka ACG2, ANFH, ANFH1, AOM, COL11A3, EDMMD}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314] {aka CHDS6, MMP-3, SL-1, STMY, STMY1, STR1}, Ezh2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) [NCBI Gene 312299], TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Igf1 (insulin-like growth factor 1) [NCBI Gene 24482] {aka IGF}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, BMP7 (bone morphogenetic protein 7) [NCBI Gene 655] {aka OP-1}, ADAMTS4 (ADAM metallopeptidase with thrombospondin type 1 motif 4) [NCBI Gene 9507] {aka ADAMTS-2, ADAMTS-4, ADMP-1}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, Adamts1 (ADAM metallopeptidase with thrombospondin type 1 motif 1) [NCBI Gene 11504] {aka ADAM-TS1, ADAMTS, ADAMTS-1, C3-C5, METH-1, METH1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) [NCBI Gene 2146] {aka ENX-1, ENX1, EZH2b, KMT6, KMT6A, WVS}, TNFRSF11B (TNF receptor superfamily member 11b) [NCBI Gene 4982] {aka OCIF, OPG, PDB5, TR1}
- **Diseases:** TMJOA (MESH:D013706), knee osteoarthritis (MESH:D020370), teratoma (MESH:D013724), bone sclerosis (MESH:D001847), joint damage (MESH:D007592), intra-articular inflammation (MESH:D057072), acidosis (MESH:D000138), subchondral bone defects (MESH:D001845), infection (MESH:D007239), coagulopathies (MESH:D001778), cardiovascular sequelae (MESH:D002318), gastrointestinal mucosal damage (MESH:D005767), hypertrophy (MESH:D006984), synovitis (MESH:D013585), tumorigenic (MESH:D002471), stiffness (MESH:C566112), arthritis (MESH:D001168), RA (MESH:D001172), joint injury (MESH:D000092464), joint degeneration (MESH:D009410), deformity (MESH:D009140), swelling (MESH:D004487), calcification (MESH:D002114), Pain (MESH:D010146), mitochondrial deterioration (MESH:D028361), degenerative joint disease (MESH:D019636), Cartilage inflammation (MESH:D007249), muscle atrophy (MESH:D009133), articular cartilage defects (MESH:D002357), analgesia (MESH:D000699), OA (MESH:D010003), arthritic joint (MESH:D015535), mechanical disorders (MESH:D013285), sclerosis (MESH:D012598)
- **Chemicals:** PCL (MESH:C016240), fatty acid (MESH:D005227), arginine (MESH:D001120), poly(vinyl alcohol) (MESH:D011142), beta-glycerophosphate (MESH:C031463), sulfhydryl (MESH:D013438), Cyclodextrin (MESH:D003505), doxorubicin (MESH:D004317), GAG (MESH:D006025), phenylboronic acid (MESH:C010686), hydroxyproline (MESH:D006909), imine (MESH:D007097), disulfide (MESH:D004220), G1-NC5.HCl@siRNA (-), polyphosphazene (MESH:C108974), curcumin (MESH:D003474), Melatonin (MESH:D008550), poly(beta-amino ester) (MESH:C507253), calcium (MESH:D002118), berberine (MESH:D001599), ROS (MESH:D017382), PLGA (MESH:D000077182), poly(N-isopropyl acrylamide (MESH:C052970), dopamine (MESH:D004298), hydrogen (MESH:D006859), ammonia borane (MESH:C000726505), adamantane (MESH:D000218), lipid (MESH:D008055), poly(vinylamine) (MESH:C008996), ATP (MESH:D000255), benzophenone (MESH:C047723), PAMAM (MESH:C531249), Ester (MESH:D004952), Rapamycin (MESH:D020123), thione (MESH:D013871), polymer (MESH:D011108), polysaccharide (MESH:D011134), graphene oxide (MESH:C000628730), PEG (MESH:D011092), LiMn2O4 (MESH:C488552), beta-CD (MESH:C031215), carboxylic acid (MESH:D002264), acids (MESH:D000143), CS (MESH:D048271), boronic acid (MESH:D001897), KGN (MESH:C572342), poly(N, N-diethylacrylamide) (MESH:C428028), acetaminophen (MESH:D000082), oxygen (MESH:D010100), Alg (MESH:D000464), GA (MESH:D005707), metal (MESH:D008670), chondroitin sulfate (MESH:D002809), poly(gamma-glutamic acid) (MESH:C511775), Infliximab (MESH:D000069285), HA (MESH:D006820), mPDA (MESH:C056728), polydopamine (MESH:C568283), polylysine (MESH:D011107), CMC (MESH:C514968)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Bos taurus (bovine, species) [taxon 9913], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Mus musculus (house mouse, species) [taxon 10090], Adeno-associated virus (species) [taxon 272636], Sus scrofa (pig, species) [taxon 9823]
- **Cell lines:** hESCs — Homo sapiens (Human), Embryonic stem cell (CVCL_UI95)

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12962237/full.md

---
Source: https://tomesphere.com/paper/PMC12962237